Literature DB >> 12077289

Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle.

Pamela A Kozlowski1, Selvi B Williams, Rebecca M Lynch, Timothy P Flanigan, Rosalyn R Patterson, Susan Cu-Uvin, Marian R Neutra.   

Abstract

A cholera vaccine containing killed vibrios and cholera toxin B subunit (CTB) was used to compare mucosal immunization routes for induction of systemic and mucosal Ab. Four groups of women were given three monthly immunizations by the rectal immunization (R(imm)) route, nasal immunization (N(imm)) route, or vaginal immunization route during either the follicular (V-FP(imm)) or luteal (V-LP(imm)) menstrual cycle phase. N(imm) was performed with 10-fold less vaccine to determine if administration of less Ag by this route can, as in rodents, produce mucosal Ab responses comparable to those induced by higher dose R(imm) or vaginal immunization. Concentrations of Ab induced in sera and secretions were measured by ELISA. None of these routes produced durable salivary Ab responses. N(imm) induced greatest levels of CTB-specific IgG in sera. R(imm) failed to generate CTB-specific IgA in genital tract secretions. N(imm), V-FP(imm), and V-LP(imm) all produced cervical CTB-specific IgA responses comparable in magnitude and frequency. However, only V-FP(imm) induced cervical IgA2-restricted Ab to the bacterial LPS vaccine component. V-FP(imm), but not V-LP(imm), also induced CTB-specific IgA in rectal secretions. N(imm) was superior to V-FP(imm) for producing rectal CTB-specific IgA, but the greatest amounts of CTB-specific IgA and LPS-specific IgA, IgG, and IgM Ab were found in rectal secretions of R(imm) women. These data suggest that in women, N(imm) alone could induce specific Ab in serum, the genital tract, and rectum. However, induction of genital tract and rectal Ab responses of the magnitude generated by local V-FP(imm) or R(imm) will likely require administration of comparably high nasal vaccine dosages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077289     DOI: 10.4049/jimmunol.169.1.566

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  84 in total

1.  Intranasal vaccination with the recombinant Listeria monocytogenes ΔactA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA.

Authors:  Jin Qiu; Lin Yan; Jianbo Chen; Crystal Y Chen; Ling Shen; Norman L Letvin; Barton F Haynes; Nancy Freitag; Lijun Rong; James T Frencher; Dan Huang; Xunming Wang; Zheng W Chen
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

2.  Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant.

Authors:  Richard Malley; Sarah C Morse; Luciana C C Leite; Ana Paula Mattos Areas; Paulo Lee Ho; Flavia S Kubrusly; Igor C Almeida; Porter Anderson
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

Review 3.  Improving immunity in the elderly: current and future lessons from nonhuman primate models.

Authors:  Christine Meyer; Amelia Kerns; Kristen Haberthur; Ilhem Messaoudi
Journal:  Age (Dordr)       Date:  2011-12-20

4.  Accelerated immune senescence and reduced response to vaccination in ovariectomized female rhesus macaques.

Authors:  Flora Engelmann; Alex Barron; Henryk Urbanski; Martha Neuringer; Steven G Kohama; Byung Park; Ilhem Messaoudi
Journal:  Age (Dordr)       Date:  2010-09-03

Review 5.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 6.  Endocrine control of mucosal immunity in the female reproductive tract: impact of environmental disruptors.

Authors:  B Dunbar; M Patel; J Fahey; C Wira
Journal:  Mol Cell Endocrinol       Date:  2012-01-25       Impact factor: 4.102

7.  Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.

Authors:  Nathalie Parez; Cynthia Fourgeux; Ali Mohamed; Catherine Dubuquoy; Mathieu Pillot; Axelle Dehee; Annie Charpilienne; Didier Poncet; Isabelle Schwartz-Cornil; Antoine Garbarg-Chenon
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 8.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

9.  Chitosan enhances nanoparticle delivery from the reproductive tract to target draining lymphoid organs.

Authors:  Jaehyung Park; Renuka Ramanathan; Linhchi Pham; Kim A Woodrow
Journal:  Nanomedicine       Date:  2017-04-20       Impact factor: 5.307

10.  Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Diagn Lab Immunol       Date:  2005-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.